STAA / STAAR Surgical Company - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro

Table 1: Transaction Valuation

Calculation of Filing Fee Tables Table 1: Transaction Valuation Proposed Maximum Aggregate Value of Transaction Fee Rate Amount of Filing Fee Fees to be Paid 1 $ 1,473,644,888.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

PREM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

PART I – FINANCIAL INFORMATION PART II – OTHER INFORMATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 27, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR Surgical Company (Exact Name of Registr

STAAR Surgical Reports Second Quarter 2025 Results

Exhibit 99.1 STAAR Surgical Reports Second Quarter 2025 Results LAKE FOREST, CA, August 6, 2025 - STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the second quarter ended June 27, 2025. Second Quarter 2025 Financial Overview • Net sales of $44.3 million down 55%

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2025 STAAR Surgical Compa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2025 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Letter of the Company dated June 25, 2025 to Deborah Andrews, Chief Financial Officer, regarding employment and compensation

Exhibit 10.1 June 25, 2025 Dear Deborah: On behalf of STAAR Surgical Company (“STAAR”), I want to thank you for your contributions to STAAR’s success as Interim Chief Financial Officer. As we discussed, STAAR is pleased to offer you the position of Chief Financial Officer, reporting to Stephen Farrell, Chief Executive Officer, effective June 25, 2025. Your new annual base salary will be $495,000,

Consulting Agreement dated April 24, 2025 between the Company and Wei Jiang.

Exhibit 10.2 CONSULTING AGREEMENT This Consulting Agreement (“Agreement”) is entered into an effective as of April 24, 2025 (the “Effective Date”), by and between STAAR Surgical Company, a Delaware corporation on behalf of itself and any and all affiliated entities (together, the “Company”) and Wei Jiang (the “Consultant”). RECITALS A. The Company is a leading developer, manufacturer and marketer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro

Agreement and Plan of Merger, dated as of August 4, 2025, by and among STAAR Surgical Company, Alcon Research, LLC and Rascasse Merger Sub, Inc

EX-2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among STAAR SURGICAL COMPANY, a Delaware corporation, ALCON RESEARCH, LLC, a Delaware limited liability company, and RASCASSE MERGER SUB, INC., a Delaware corporation Dated as of August 4, 2025 Table of Contents Page SECTION 1 THE MERGER 1.1 The Closing 2 1.2 The Merger 3 1.3 Conversion of Shares 2 1.4 Surrender of Certificat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro

1

EX-99.1 Exhibit 99.1 Alcon Agrees to Acquire STAAR Surgical • STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes • Acquisition of STAAR is complementary to Alcon’s laser vision correction business and is expected to be accretive in year two • Alcon to purchase all outstanding shares of STAAR for $28 per share in cash,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 STAAR Surgical Com

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 STAAR Surgical Company (Exact name of registrant as specified in its charter) Delaware 0-11634 95-3797439 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 STAAR Surgical Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 STAAR Surgical Company (Exact name of registrant as specified in its charter) Delaware 0-11634 95-3797439 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro

STAAR Surgical Announces Appointment of Deborah Andrews as Chief Financial Officer Forms Capital Stewardship Committee of the Board of Directors

Exhibit 99.1 STAAR Surgical Announces Appointment of Deborah Andrews as Chief Financial Officer Forms Capital Stewardship Committee of the Board of Directors LAKE FOREST, CA – June 25, 2025 - STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that Deborah Andrews has been appo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 25, 2025 STAAR Surgical Compan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 25, 2025 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 18, 2025 STAAR Surgical Compan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 18, 2025 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Non-GAAP Financial Information To supplement the Company’s financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), this presentation and the accompanying tables include certain non-GAAP financial measures,

NASDAQ: STAA Investor Presentation June 2025 Addressing the myopia epidemic as the global leader in phakic IOLs for vision correction Exhibit 99.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 4, 2025 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 16, 2025 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAAR Surgical Announces $30 Million Share Repurchase Authorization

Exhibit 99.1 STAAR Surgical Announces $30 Million Share Repurchase Authorization LAKE FOREST, CA, May 16, 2025 - STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up t

STAAR Surgical Reports First Quarter 2025 Results China ICL Procedure Trends Improving Tariff Mitigation Activities Implemented Cost Controls and Restructuring Initiated to Reduce SG&A Run Rate Earnings Call and Webcast Today at 5:15 p.m. Eastern

Exhibit 99.1 STAAR Surgical Reports First Quarter 2025 Results China ICL Procedure Trends Improving Tariff Mitigation Activities Implemented Cost Controls and Restructuring Initiated to Reduce SG&A Run Rate Earnings Call and Webcast Today at 5:15 p.m. Eastern LAKE FOREST, CA, May 7, 2025 - STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Co

Form of Performance Stock Unit Grant and Agreement

Exhibit 10.3 |||| STAAR Surgical Company PERFORMANCE STOCK UNIT AWARD GRANT NOTICE STAAR Surgical Company, a Delaware corporation, (the “Company”), has granted to the participant identified below (the “Participant”) an award (the “Award”) of the number of performance stock units (“Performance Stock Units” or “PSUs”) specified below in this Performance Stock Unit Award Grant Notice (the “Grant Noti

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2025 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

PART I – FINANCIAL INFORMATION PART II – OTHER INFORMATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 28, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR Surgical Company (Exact Name of Regist

STAAR Surgical Earnings Call and Webcast First Quarter 2025 STEPHEN FARRELL Chief Executive Officer WARREN FOUST DEBORAH ANDREWS President and Chief Operating Officer Interim Chief Financial Officer Today’s Speakers 02 Webcast participants may also e

NASDAQ: STAA First Quarter 2025 Earnings Call and Webcast Presentation MAY 7, 2025 Addressing the myopia epidemic as the global leader in phakic IOLs for vision correction Exhibit 99.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 24, 2025 STAAR Surgical Compa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 24, 2025 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAAR Surgical Announces Changes to Board of Directors

Exhibit 99.1 STAAR Surgical Announces Changes to Board of Directors LAKE FOREST, CA – April 24, 2025 - STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

STAAR Surgical Announces Realignment of Leadership Structure Warren Foust Named President and Chief Operating Officer Magda Michna, PhD Appointed Chief Development Officer Deborah Andrews, STAAR’s Chief Financial Officer from 2017- 2020, to serve as

Exhibit 99.1 STAAR Surgical Announces Realignment of Leadership Structure Warren Foust Named President and Chief Operating Officer Magda Michna, PhD Appointed Chief Development Officer Deborah Andrews, STAAR’s Chief Financial Officer from 2017- 2020, to serve as Interim Chief Financial Officer Patrick F. Williams Steps Down as Chief Financial Officer Keith Holliday Retires as Chief Technology Offi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 17, 2025 STAAR Surgical Compa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 17, 2025 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Amended and Restated Bylaws

Exhibit 3.1 AMENDED AND RESTATED BYLAWS STAAR Surgical Company (a Delaware Corporation) ARTICLE I Offices SECTION 1. Registered Office. The registered office of the Corporation within the State of Delaware shall be as set forth in the Corporation’s certificate of incorporation (as the same may be amended and/or restated from time to time, the “Certificate of Incorporation”). SECTION 2. Other Offic

STAAR Surgical Announces Leadership Transition Stephen C. Farrell appointed CEO to succeed Tom Frinzi Elizabeth Yeu, M.D. elected Board Chair

Exhibit 99.1 STAAR Surgical Announces Leadership Transition Stephen C. Farrell appointed CEO to succeed Tom Frinzi Elizabeth Yeu, M.D. elected Board Chair LAKE FOREST, CA, February 26, 2025 - STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced a leadership transition. Stephen C

Employment Agreement, effective February 26, 2025, by and between the Company and Stephen C. Farrell

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is entered into and effective as of February 26, 2025 (the “Effective Date”), by and between STAAR Surgical Company, a Delaware corporation on behalf of itself and any and all affiliated entities (together, the “Company”) and Stephen C. Farrell (“Executive”). RECITALS A. The Company is a leading developer, manufacturer and m

Consulting Agreement, effective February 26, 2025, by and between the Company and Thomas G. Frinzi

Exhibit 10.2 CONSULTING AGREEMENT This Consulting Agreement (“Agreement”) is entered into an effective as of February 26, 2025 (the “Effective Date”), by and between STAAR Surgical Company, a Delaware corporation on behalf of itself and any and all affiliated entities (together, the “Company”) and Thomas G. Frinzi (the “Consultant”). RECITALS A. The Company is a leading developer, manufacturer and

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 26, 2025 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Insider Trading Policy.

Exhibit 19.1 Last Updated: October 3, 2024 Insider Trading Policy TABLE OF CONTENTS 1. Purpose and Policy 2. Persons Subject to this Policy 3. Transactions Subject to this Policy 4. Definition of Material Information 5. Definition of Nonpublic Information 6. Prohibited Activities 7. Restrictions on Certain Transactions 8. Trading Blackout Periods for Restricted Persons 9. Pre-Clearance Requirement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 e Form 10-K c (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 27, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-11634 STAAR SURGIC

List of Subsidiaries.

Exhibit 21.1 Subsidiaries of STAAR Surgical Company Name of Subsidiary Other Names Under Which it Does Business State or Other Jurisdiction of Incorporation STAAR Surgical UK LTD None United Kingdom STAAR Surgical AG None Switzerland STAAR Japan Inc. STAAR Surgical Kabushiki Kaisha Japan STAAR Surgical PTE. LTD None Singapore STAAR Optical Equipment Technology (Shanghai) Co., LTD None China STAAR

NASDAQ: STAA February 11, 2025 Fourth Quarter and Fiscal 2024

NASDAQ: STAA February 11, 2025 Fourth Quarter and Fiscal 2024 Earnings Presentation Exhibit 99.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 11, 2025 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAAR Surgical Reports Fourth Quarter and Fiscal Year 2024 Results Net Sales of $313.9 Million and ICL Sales of $312.5 Million for Fiscal 2024 Impacted by Weak China Macroeconomic Conditions ICL Sales Ex. China Up 17% in Fourth Quarter and 13% in Fis

Exhibit 99.1 STAAR Surgical Reports Fourth Quarter and Fiscal Year 2024 Results Net Sales of $313.9 Million and ICL Sales of $312.5 Million for Fiscal 2024 Impacted by Weak China Macroeconomic Conditions ICL Sales Ex. China Up 17% in Fourth Quarter and 13% in Fiscal 2024 Introduces Outlook for Fiscal 2025 Earnings Conference Call and Webcast Today at 5:00 p.m. Eastern LAKE FOREST, CA, February 11,

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 13, 2025 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAAR Surgical to Host Fourth Quarter and Fiscal Year 2024 Earnings Conference Call and Webcast on February 19, 2025

Exhibit 99.1 STAAR Surgical to Host Fourth Quarter and Fiscal Year 2024 Earnings Conference Call and Webcast on February 19, 2025 LAKE FOREST, CA, January 13, 2025 - STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarte

STAAR Surgical Reports Third Quarter 2024 Results Net Sales Up 10% to $88.6 Million Driven by Growth in All Regions Americas Up 14%, EMEA Up 12% and APAC Up 9% Market Building Initiatives Drive EVO ICL™ Uptake and Reinforce Opportunity

Exhibit 99.1 STAAR Surgical Reports Third Quarter 2024 Results Net Sales Up 10% to $88.6 Million Driven by Growth in All Regions Americas Up 14%, EMEA Up 12% and APAC Up 9% Market Building Initiatives Drive EVO ICL™ Uptake and Reinforce Opportunity LAKE FOREST, CA, October 30, 2024 - STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implanta

NASDAQ: STAA Third Quarter 2024

NASDAQ: STAA Third Quarter 2024 Earnings Presentation OCTOBER 30, 2024 Exhibit 99.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 30, 2024 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

NASDAQ: STAA Third Quarter 2024

NASDAQ: STAA Third Quarter 2024 Earnings Presentation OCTOBER 30, 2024 Exhibit 99.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 27, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR Surgical Company (Exact Name of Re

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 30, 2024 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAAR Surgical Reports Third Quarter 2024 Results Net Sales Up 10% to $88.6 Million Driven by Growth in All Regions Americas Up 14%, EMEA Up 12% and APAC Up 9% Market Building Initiatives Drive EVO ICL™ Uptake and Reinforce Opportunity

Exhibit 99.1 STAAR Surgical Reports Third Quarter 2024 Results Net Sales Up 10% to $88.6 Million Driven by Growth in All Regions Americas Up 14%, EMEA Up 12% and APAC Up 9% Market Building Initiatives Drive EVO ICL™ Uptake and Reinforce Opportunity LAKE FOREST, CA, October 30, 2024 - STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implanta

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2024 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

2 STAAR Surgical Earnings Webcast Second Quarter 2024 Today’s Speakers Investor Relations PATRICK WILLIAMS TOM FRINZI Chair of the Board, President and CEO Chief Financial Officer +1 626.303.7902 x3023 Brian Moore VP, Investor Relations and Corporate

NASDAQ: STAA Second Quarter 2024 Earnings Presentation August 7, 2024 Exhibit 99.2 2 STAAR Surgical Earnings Webcast Second Quarter 2024 Today’s Speakers Investor Relations PATRICK WILLIAMS TOM FRINZI Chair of the Board, President and CEO Chief Financial Officer +1 626.303.7902 x3023 Brian Moore VP, Investor Relations and Corporate Development Connie Johnson Niko Liu, CFA Director, Investor Relati

STAAR Surgical Reports Second Quarter 2024 Results Record Quarterly Net Sales of $99.0 Million; $100.4 Million in Constant Currency Raises Fiscal 2024 Net Sales and Adjusted EBITDA Outlook

Exhibit 99.1 STAAR Surgical Reports Second Quarter 2024 Results Record Quarterly Net Sales of $99.0 Million; $100.4 Million in Constant Currency Raises Fiscal 2024 Net Sales and Adjusted EBITDA Outlook LAKE FOREST, CA, August 7, 2024 - STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astig

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 28, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR Surgical Company (Exact Name of Registr

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 20, 2024 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAAR Surgical Company Amended and Restated Omnibus Equity Incentive Plan

Exhibit 10.1 STAAR SURGICAL COMPANY AMENDED AND RESTATED OMNIBUS EQUITY INCENTIVE PLAN ARTICLE 1. PURPOSE The purpose of the STAAR Surgical Company Amended and Restated Omnibus Equity Incentive Plan (as it may be amended or restated from time to time, the “Plan”) is to promote the success and enhance the value of STAAR Surgical Company (the “Company”) by linking the individual interests of the mem

Filing Fee Table.

Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) STAAR Surgical Company (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Equity Common Stock,

Amendment No. 1 to the STAAR Surgical Company Amended and Restated Omnibus Equity Incentive Plan

Exhibit 10.2 AMENDMENT NO. 1 TO THE STAAR SURGICAL COMPANY AMENDED AND RESTATED OMNIBUS EQUITY INCENTIVE PLAN This Amendment No. 1 (the “Amendment”) to the STAAR Surgical Company Amended and Restated Omnibus Equity Incentive Plan (the “Plan”) is adopted by the Board of Directors (“Board”) of STAAR Surgical Company, a Delaware corporation (the “Company”) on March 28, 2024. This Amendment will becom

As filed with the Securities and Exchange Commission on June 21, 2024

As filed with the Securities and Exchange Commission on June 21, 2024 Registration No.

All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections, anticipated financial results, estimates and outlook (including as to net sales, Adj

NASDAQ: STAA Investor Presentation June 12, 2024 Exhibit 99.1 All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections, anticipated financial results, estimates and outlook (including as to net sales, Adjusted EBITDA, and Adjusted EBITDA per diluted share), plans, strategies, and objectives

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2024 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAAR Surgical Reports First Quarter 2024 Results EVO ICL™ Continues to Outpace Refractive Industry Growth Record Quarterly U.S. Sales and Multiple Strategic Agreements Secured Reiterates Fiscal 2024 Net Sales Outlook and Increases Adjusted EBITDA

Exhibit 99.1 STAAR Surgical Reports First Quarter 2024 Results EVO ICL™ Continues to Outpace Refractive Industry Growth Record Quarterly U.S. Sales and Multiple Strategic Agreements Secured Reiterates Fiscal 2024 Net Sales Outlook and Increases Adjusted EBITDA LAKE FOREST, CA, May 7, 2024 - STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 29, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR Surgical Company (Exact Name of Regist

NASDAQ: STAA 1Q 2024

NASDAQ: STAA 1Q 2024 Earnings Call Supplement MAY 7, 2024 Exhibit 99.2 02 Conference Call and Webcast Speakers Investor Contact TOM FRINZI PATRICK WILLIAMS Chair of the Board, President and CEO Chief Financial Officer WEBCAST ARCHIVE: Audio webcast archive will be available at http://investors.staar.com +1 626.303.7902 x3023 Brian Moore VP, Investor Relations and Corporate Development bmoore@staar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2024 STAAR Surgical Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2024 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024 Total Net Sales in Excess of $77 Million Including Record Quarterly U.S. ICL Sales of $5 Million

Exhibit 99.1 STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024 Total Net Sales in Excess of $77 Million Including Record Quarterly U.S. ICL Sales of $5 Million LAKE FOREST, CA, April 4, 2024-STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 4, 2024 STAAR Surgical Compan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 4, 2024 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections, anticipated financial results, estimates and outlook (including as to net sales, Adj

NASDAQ: STAA Investor Presentation March 2024 Exhibit 99.1 All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections, anticipated financial results, estimates and outlook (including as to net sales, Adjusted EBITDA, and Adjusted EBITDA per diluted share), plans, strategies, and objectives of

STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses

Exhibit 99.2 STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses LAKE FOREST, CA, March 18, 2024- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that more than three million ICLs have been sold globally.1 “We extend our sincere

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 18, 2024 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directors

Exhibit 99.1 STAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directors LAKE FOREST, CA, March 12, 2024 - STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Arthur Butcher, Executive Vice President and Group President, Med

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2024 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

25651 Atlantic Ocean Drive | Lake Forest, CA 92630 | (626) 303-7902

February 28, 2024 VIA EDGAR TRANSMISSION United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.

FEBRUARY 26, 2024 / 9:15PM, STAA.OQ - Q4 2023 STAAR Surgical Co Earnings Call

Exhibit 99.1 FEBRUARY 26, 2024 / 9:15PM, STAA.OQ - Q4 2023 STAAR Surgical Co Earnings Call FEBRUARY 26, 2024 / 9:15PM, STAA.OQ - Q4 2023 STAAR Surgical Co Earnings Call C O R P O R A T E P A R T I C I P A N T S Brian Moore STAAR Surgical Co - Investor Relation, Vice President, Media Relations, Corporate Development Thomas Frinzi STAAR Surgical Co - President and Chief Executive Officer Patrick Wil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 26, 2024 STAAR Surgical Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 26, 2024 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Form of Executive Change in Control Agreement between the Company and certain officers

Exhibit 10.3 STAAR SURGICAL COMPANY CHANGE IN CONTROL AGREEMENT THIS CHANGE IN CONTROL AGREEMENT (this "Agreement"), dated as of is made by and between STAAR Surgical Company, a Delaware corporation (the "Company"), and ("Executive"). WITNESSETH: WHEREAS, Executive is an executive of the Company and has made and is expected to continue to make significant contributions to the short- and long-term

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 29, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-11634 STAAR SURGICAL C

Letter of the Company, dated October 24, 2023 to Nathaniel Sisitsky, General Counsel, regarding compensation

Exhibit 10.13 October 24, 2023 Dear Nate: STAAR Surgical Company is pleased to offer you the position of General Counsel and Corporate Secretary reporting to Tom Frinzi, President and Chief Executive Officer. Your beginning wage will be $18,076.93 per bi-weekly pay period ($470,000 annually), in addition to all the benefits offered through our current policies. As approved by the Compensation Comm

List of Subsidiaries.

Exhibit 21.1 Subsidiaries of STAAR Surgical Company Name of Subsidiary Other Names Under Which it Does Business State or Other Jurisdiction of Incorporation STAAR Surgical UK LTD None United Kingdom STAAR Surgical AG None Switzerland STAAR Japan Inc. STAAR Japan Godo Kaisha Japan STAAR Surgical PTE. LTD None Singapore STAAR Optical Equipment Technology (Shanghai) Co., LTD None China STAAR Surgical

Second Amendment to Lease Agreement dated November 15, 2023 between the Company and Bukewihge Properties, LLC

Exhibit 10.27 THIS SECOND AMENDMENT TO LEASE is made and entered into as of November 15, 2023 by and between Bukewihge Properties, LLC (a California limited liability company) (“Lessor”) and Staar Surgical Company (a Delaware corporation) ("Lessee"). WHEREAS, pursuant to said Lease dated March 19, 2018, Lessor did lease to Lessee and Lessee did lease from Lessor that certain approximately 20,608 s

Tenth Amendment of Lease dated May 13, 2022, by and between the Company and Oxford Spectrum Wilson LLC

Exhibit 10.20 TENTH AMENDMENT OF LEASE This Tenth Amendment of Lease ("Tenth Amendment") is made this 24th day of May 2022, by and between Oxford Spectrum Wilson LLC, a California Limited Liability Company, (hereinafter called "Lessor") and Staar Surgical Company, a Delaware corporation (hereinafter called "Lessee"). RECITALS: A. Lessor and Lessee have heretofore entered into that certain Commerci

First Amendment to Lease Agreement dated March 23, 2023 between the Company and 2000 Gold L.P.

Exhibit 10.24 First AMENDMENT TO LEASE THIS AMENDMENT TO LEASE is made and entered into as of March 23, 2023, by and between 2000 Gold L.P. ("Lessor") and STAAR Surgical Company, a Delaware corporation (“Lessee"). WHEREAS, on or about August 10, 2017 a lease was entered into by and between Lessor and Lessee relating to certain real property commonly known as (street address, city, state, zip): 191

Compensation Recoupment (Clawback) Policy

Exhibit 97.1 STAAR SURGICAL COMPANY Compensation Recoupment (Clawback) Policy Recoupment of Incentive-Based Compensation It is the policy of STAAR Surgical Company (the “Company”) that, in the event the Company is required to prepare an accounting restatement of the Company’s financial statements due to material non-compliance with any financial reporting requirement under the federal securities l

STAAR Surgical Reports Fourth Quarter and Fiscal Year 2023 Results Generates Double-Digit Sales Growth and Continuing Profitability ICL Sales Up 22% in Fourth Quarter and 18% in Fiscal 2023 Affirms Sales Outlook for Fiscal 2024

Exhibit 99.1 STAAR Surgical Reports Fourth Quarter and Fiscal Year 2023 Results Generates Double-Digit Sales Growth and Continuing Profitability ICL Sales Up 22% in Fourth Quarter and 18% in Fiscal 2023 Affirms Sales Outlook for Fiscal 2024 LAKE FOREST, CA, February 26, 2024 - STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Col

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 26, 2024 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAA / STAAR Surgical Company / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01981-staarsurgicalco.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: STAAR Surgical Co Title of Class of Securities: Common Stock CUSIP Number: 852312305 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate

25651 Atlantic Ocean Drive | Lake Forest, CA 92630 | (626) 303-7902

January 31, 2024 VIA EDGAR TRANSMISSION United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.

STAA / STAAR Surgical Company / BROADWOOD PARTNERS, L.P. Activist Investment

SC 13D/A 1 d1093116713d-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 31) STAAR Surgical Company (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 852312305 (CUSIP Number) Neal C. Bradsher c/o Broadwood Capital, Inc. 142 West 57th Street, 11th Floor New York, New York

03 STAAR Surgical / Our Vision The first Choice for Doctors and Patients Seeking Visual Freedom

NASDAQ: STAA Investor Presentation January 2024 Exhibit 99.2 All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2024 and beyond or prospects for achieving such plans, expectations for sales, revenue, margin, expense

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2024 STAAR Surgical Comp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2024 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAAR Surgical Announces Preliminary Results for Fourth Quarter and Fiscal 2023 Net Sales Up 19% for Fourth Quarter and 13% for Fiscal 20231 ICL Sales Up 22% for Fourth Quarter and 18% for Fiscal 2023 Provides Fiscal 2024 Sales Outlook of $335 Millio

Exhibit 99.1 STAAR Surgical Announces Preliminary Results for Fourth Quarter and Fiscal 2023 Net Sales Up 19% for Fourth Quarter and 13% for Fiscal 20231 ICL Sales Up 22% for Fourth Quarter and 18% for Fiscal 2023 Provides Fiscal 2024 Sales Outlook of $335 Million to $340 Million LAKE FOREST, CA, January 8, 2024 - STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and markete

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 1, 2023 STAAR Surgical Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 1, 2023 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Lilian Zhou Appointed to STAAR Surgical Board of Directors

Exhibit 99.1 Lilian Zhou Appointed to STAAR Surgical Board of Directors LAKE FOREST, CA, December 4, 2023 - STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Lilian Zhou to its Board of Directors, effective December 4, 2023. “We welc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 16, 2023 STAAR Surgical Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 16, 2023 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

03 STAAR Surgical / Our Vision The first Choice for Doctors and Patients Seeking Visual Freedom

NASDAQ: STAA Investor Presentation November 2023 Exhibit 99.1 All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2023 and beyond or prospects for achieving such plans, expectations for sales, revenue, margin, expens

STAA / Staar Surgical Co. / BROADWOOD PARTNERS, L.P. Activist Investment

SC 13D/A 1 d1087733913d-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 30) STAAR Surgical Company (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 852312305 (CUSIP Number) Neal C. Bradsher c/o Broadwood Capital, Inc. 142 West 57th Street, 11th Floor New York, New York

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 29, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR Surgical Company (Exact Name of Re

NOVEMBER 01, 2023 / 8:30PM, STAA.OQ - Q3 2023 STAAR Surgical Co Earnings Call

Exhibit 99.1 NOVEMBER 01, 2023 / 8:30PM, STAA.OQ - Q3 2023 STAAR Surgical Co Earnings Call C O R P O R A T E P A R T I C I P A N T S Brian Moore STAAR Surgical Company - VP of Investor, Media Relations & Corporate Development Patrick F. Williams STAAR Surgical Company - CFO Thomas G. Frinzi STAAR Surgical Company - President, CEO & Chairman C O N F E R E N C E C A L L P A R T I C I P A N T S Antho

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2023 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAAR Surgical Reports Third Quarter 2023 Results Net Sales of $80.3 Million; ICL Sales of $81.1 Million Up 13% Y/Y 23rd Consecutive Quarter of Double-Digit ICL Sales Growth1

EX-99.1 2 staa-ex991.htm EX-99.1 Exhibit 99.1 STAAR Surgical Reports Third Quarter 2023 Results Net Sales of $80.3 Million; ICL Sales of $81.1 Million Up 13% Y/Y 23rd Consecutive Quarter of Double-Digit ICL Sales Growth1 LAKE FOREST, CA, November 1, 2023 - STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) f

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2023 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAA / Staar Surgical Co. / BROADWOOD PARTNERS, L.P. Activist Investment

SC 13D/A 1 d1083562013d-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 29) STAAR Surgical Company (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 852312305 (CUSIP Number) Neal C. Bradsher c/o Broadwood Capital, Inc. 142 West 57th Street, 11th Floor New York, New York

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 14, 2023 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Amended Slide 108 of presentation dated September 14, 2023

108 STAAR Knows How to Generate Cash (in millions) * Initial sales outlook provided prior to COVID on January 13, 2020, was for sales mid-point of $177 million or +18% Y/Y Growth for 2020.

STAAR Surgical VISION 2026 STAAR Surgical Investor Day September14,2023 NASDAQ:STAA

Exhibit 99.1 STAAR Surgical VISION 2026 STAAR Surgical Investor Day September14,2023 NASDAQ:STAA Agenda Time EDT Topic Speaker 8:30 a.m. Welcome/Safe Harbor Brian Moore, Investor Relations Vision 2026: Achieving STAAR’s Global Growth Opportunity Tom Frinzi, Chair of the Board and CEO Extending EVO ICL’s Leadership Position Magda Michna, PhD Chief Clinical, Regulatory and Medical Affairs Officer Ch

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 14, 2023 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2023 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Forward Looking Statements All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of ma

EX-99.1 Exhibit 99.1 Investor Presentation STAAR Surgical | NASDAQ: STAA August 2023 Forward Looking Statements All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2023 or prospects for achieving such plans, expectat

REFINITIV STREETEVENTS

EX-99.1 REFINITIV STREETEVENTS EDITED TRANSCRIPT STAA.OQ - Q2 2023 STAAR Surgical Co Earnings Call EVENT DATE/TIME: AUGUST 02, 2023 / 8:30PM GMT REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us ©2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without the prior written consent of Refinitiv. ‘Refin

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2023 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR Surgical Company (Exact Name of Registr

STAAR Surgical Reports Second Quarter 2023 Results Record ICL Sales of $93.1Million Up 19% Y/Y

EX-99.1 Exhibit 99.1 STAAR Surgical Reports Second Quarter 2023 Results Record ICL Sales of $93.1Million Up 19% Y/Y LAKE FOREST, CA, August 2, 2023 — STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Overview • Net Sales of $92.3 Mi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2023 STAAR Surgical Compa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2023 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2023 STAAR Surgical Compan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2023 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Company Name: STAAR Surgical Company (STAA)

Exhibit 99.1 Company Name: STAAR Surgical Company (STAA) Event: William Blair 43rd Annual Growth Stock Conference Date: June 06, 2023 <> Good afternoon everyone. Thanks for coming out to the William Blair Growth Stock Conference. My name is Margaret Kaczor. I am the Research Analyst at William Blair, who covers STAAR Surgical. I am required to inform you that you can obtain a complete list of rese

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2023 STAAR Surgical Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2023 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2023 or prospe

Investor Presentation June 2023 STAAR Surgical | NASDAQ: STAA Exhibit 99.1 All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2023 or prospects for achieving such plans, expectations for sales, revenue, margin, expe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2023 STAAR Surgical Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2023 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

MAY 03, 2023 / 8:30PM, STAA.OQ - Q1 2023 STAAR Surgical Co Earnings Call

Exhibit 99.1 MAY 03, 2023 / 8:30PM, STAA.OQ - Q1 2023 STAAR Surgical Co Earnings Call C O R P O R A T E P A R T I C I P A N T S Brian Moore STAAR Surgical Company - VP of Investor, Media Relations & Corporate Development Patrick F. Williams STAAR Surgical Company - CFO Thomas G. Frinzi STAAR Surgical Company - President, CEO & Chairman C O N F E R E N C E C A L L P A R T I C I P A N T S AnthonyCha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 3, 2023 STAAR Surgical Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 3, 2023 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Form of Severance Agreement between the Company and certain executives

EXHIBIT 10.31 STAAR SURGICAL COMPANY SEVERANCE AGREEMENT THIS SEVERANCE AGREEMENT (this "Agreement"), dated as of (Date), is made by and between STAAR Surgical Company, a Delaware corporation (the "Company"), and (Executive Name) ("Executive"). WITNESSETH: WHEREAS, Executive is an executive of the Company and has made and is expected to continue to make significant contributions to the short- and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 3, 2023 STAAR Surgical Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 3, 2023 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAAR Surgical Reports First Quarter 2023 Results Q1 2023 Net Sales of $73.5 Million; ICL Sales of $70.6 Million Up 20% Y/Y Fiscal 2023 Net Sales Outlook Raised to $348 Million; ICL Sales to $345 Million Up 28% Y/Y

Exhibit 99.1 STAAR Surgical Reports First Quarter 2023 Results Q1 2023 Net Sales of $73.5 Million; ICL Sales of $70.6 Million Up 20% Y/Y Fiscal 2023 Net Sales Outlook Raised to $348 Million; ICL Sales to $345 Million Up 28% Y/Y LAKE FOREST, CA, May 3, 2023 - STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported finan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR Surgical Company (Exact Name of Regist

Letter of the Company dated March 24, 2023 to Magda Michna, Chief Clinical, Regulatory and Medical Affairs Officer, regarding compensation

Exhibit 10.30 March 24, 2023 Dear Magda: STAAR Surgical Company is pleased to offer you the position of Chief Clinical, Regulatory and Medical Affairs Officer reporting to Tom Frinzi, President and Chief Executive Officer. Your beginning wage will be $18,269.23 per bi-weekly pay period ($475,000 annually), in addition to all the benefits offered through our current policies. Subject to approval by

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Letter of the Company dated March 24, 2023 to Warren Foust, Chief Operating Officer, regarding compensation

Exhibit 10.1 March 24, 2023 Dear Warren: STAAR Surgical Company is pleased to offer you the position of Chief Operating Officer reporting to Tom Frinzi, President and Chief Executive Officer. Your beginning wage will be $21,153.85 per bi-weekly pay period ($550,000 annually), in addition to all the benefits offered through our current policies. Subject to approval by the Compensation Committee of

STAAR Surgical Names Warren Foust Chief Operating Officer; Magda Michna, Ph.D., Chief Clinical, Regulatory and Medical Affairs Officer New Positions Demonstrate Increased Commitment and Focus on Continued Industry Leading Growth

Exhibit 99.1 STAAR Surgical Names Warren Foust Chief Operating Officer; Magda Michna, Ph.D., Chief Clinical, Regulatory and Medical Affairs Officer New Positions Demonstrate Increased Commitment and Focus on Continued Industry Leading Growth LAKE FOREST, CA, March 29, 2023 - STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, tod

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 24, 2023 STAAR Surgical Compa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 24, 2023 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2023 or prospe

Envision a Life Without Hesitation STAAR Surgical Investor Presentation NASDAQ: STAA | March 2023 Exhibit 99.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 14, 2023 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-11634 STAAR SURGICAL C

List of Subsidiaries.*

Exhibit 21.1 Subsidiaries of STAAR Surgical Company Name of Subsidiary Other Names Under Which it Does Business State or Other Jurisdiction of Incorporation STAAR Surgical UK LTD None United Kingdom STAAR Surgical AG None Switzerland STAAR Japan Inc. STAAR Japan Godo Kaisha Japan STAAR Surgical PTE. LTD None Singapore STAAR Optical Equipment Technology (Shanghai) Co., LTD None China STAAR Surgical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 21, 2023 STAAR Surgical Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 21, 2023 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

First Amendment to Lease Agreement dated August 11, 2022 between the Company and Bukewihge Properties, LLC

Exhibit 10.27 THIS FIRST AMENDMENT TO LEASE is made and entered into as of August 11, 2022 by and between Bukewihge Properties, LLC (a California limited liability company) (“Lessor”) and Staar Surgical Company (a Delaware corporation) ("Lessee"). WHEREAS, pursuant to said Lease dated March 19, 2018, Lessor did lease to Lessee and Lessee did lease from Lessor that certain approximately 20,608 squa

CORPORATE PARTICIPANTS

Exhibit 99.1 1 Exhibit 99.1 CORPORATE PARTICIPANTSBrian Moore STAAR Surgical Company - VP of Investor, Media Relations & Corporate DevelopmentPatrick F. Williams STAAR Surgical Company - CFOThomas G. Frinzi STAAR Surgical Company - President, CEO & ChairmanCONFERENCE CALL PARTICIPANTSAnthony Charles Petrone Mizuho Securities USA LLC, Research Division - MD & Senior Medical Devices, Diagnostics and

STAAR Surgical Reports Fourth Quarter and Fiscal Year 2022 Results ICL Unit Growth Up 33% Y/Y in Fiscal 2022 STAAR Reaffirms Outlook for Strong Trajectory of Growth in 2023

Exhibit 99.1 STAAR Surgical Reports Fourth Quarter and Fiscal Year 2022 Results ICL Unit Growth Up 33% Y/Y in Fiscal 2022 STAAR Reaffirms Outlook for Strong Trajectory of Growth in 2023 LAKE FOREST, CA, February 21, 2023 - STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported financial results for the fourth quarter

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 21, 2023 STAAR Surgical Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 21, 2023 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAA / STAAR Surgical Company / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01951-staarsurgicalco.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: STAAR Surgical Co. Title of Class of Securities: Common Stock CUSIP Number: 852312305 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate

Amended and Restated Bylaws

Exhibit 3.1 AMENDED AND RESTATED BYLAWS STAAR Surgical Company (a Delaware Corporation) ARTICLE I Offices SECTION 1. Registered Office. The registered office of the Corporation within the State of Delaware shall be as set forth in the Corporation’s certificate of incorporation (as the same may be amended and/or restated from time to time, the “Certificate of Incorporation”). SECTION 2. Other Offic

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 26, 2023 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2023 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAAR Surgical Reports Preliminary Sales for Fourth Quarter and Fiscal 2022 ICL Unit Growth of 20% Y/Y for the Fourth Quarter and 33% Y/Y for Fiscal 2022 U.S. ICL Units Up 109% Y/Y for the Fourth Quarter 2022 Outlook for Approximately 25% Y/Y ICL Sal

Exhibit 99.1 STAAR Surgical Reports Preliminary Sales for Fourth Quarter and Fiscal 2022 ICL Unit Growth of 20% Y/Y for the Fourth Quarter and 33% Y/Y for Fiscal 2022 U.S. ICL Units Up 109% Y/Y for the Fourth Quarter 2022 Outlook for Approximately 25% Y/Y ICL Sales Growth for Fiscal 2023 LAKE FOREST, CA, January 9, 2023 - STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and

Employment Agreement effective January 1, 2023 by and between the Company and Thomas G. Frinzi, Chief Executive Officer

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is entered into and effective as of January 1, 2023 (“Effective Date”), by and between STAAR Surgical Company, a Delaware corporation on behalf of itself and any and all affiliated entities (together, the “Company”) and Thomas G. Frinzi (“Executive”). RECITALS A. The Company is a leading developer, manufacturer and marketer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 16, 2022 STAAR Surgical Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 16, 2022 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Consulting Agreement effective January 1, 2023 by and between the Company and Caren Mason dated January 1, 2023.(22)

Exhibit 10.2 CONSULTING AGREEMENT This Consulting Agreement (“Agreement”) is made as of January 1, 2023, by and between Caren Mason, an independent consultant (“the Consultant”), and STAAR Surgical Company, a Delaware corporation, whose address is 25651 Atlantic Ocean Drive, Lake Forest, California 92630 (“the Company”), in reference to the following: RECITALS A. The Company is in the business of

STAAR Surgical CEO Caren Mason to Retire; Tom Frinzi Appointed New CEO

Exhibit 99.1 STAAR Surgical CEO Caren Mason to Retire; Tom Frinzi Appointed New CEO Ophthalmic industry executive Tom Frinzi has been appointed President & CEO of STAAR Surgical, effective January 1, 2023. Caren Mason will be retiring from STAAR Surgical on December 31, 2022, after leading the company through a significant period of revitalization and growth for more than seven years. LAKE FOREST,

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 2, 2022 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

EDITED TRANSCRIPT

EDITED TRANSCRIPT STAA.OQ - Q3 2022 STAAR Surgical Co Earnings Call EVENT DATE/TIME: NOVEMBER 02, 2022 / 8:30PM GMT Exhibit 99.1 NOVEMBER 02, 2022 / 8:30PM, STAA.OQ - Q3 2022 STAAR Surgical Co Earnings Call C O R P O R A T E P A R T I C I P A N T S Brian Moore STAAR Surgical Company - VP of Investor, Media Relations & Corporate Development Caren L. Mason STAAR Surgical Company - CEO, President & D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 2, 2022 STAAR Surgical Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 2, 2022 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR SURGICAL COMPANY (Exact Name of Re

STAAR Surgical Reports Third Quarter Net Sales of $76 Million Up 30% Y/Y ICL Units Up 40% Y/Y; Constant Currency Net Sales of $80.0 Million

Exhibit 99.1 STAAR Surgical Reports Third Quarter Net Sales of $76 Million Up 30% Y/Y ICL Units Up 40% Y/Y; Constant Currency Net Sales of $80.0 Million LAKE FOREST, CA, November 2, 2022 - STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the third quarter ende

AUGUST 10, 2022 / 8:30PM, STAA.OQ - Q2 2022 STAAR Surgical Co Earnings Call

Exhibit 99.1 AUGUST 10, 2022 / 8:30PM, STAA.OQ - Q2 2022 STAAR Surgical Co Earnings Call C O R P O R A T E P A R T I C I P A N T S Brian Moore STAAR Surgical Company - VP of Investor, Media Relations & Corporate Development Caren L. Mason STAAR Surgical Company - CEO, President & Director Patrick F. Williams STAAR Surgical Company - CFO C O N F E R E N C E C A L L P A R T I C I P A N T S Andrew Fr

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2022 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: July 1, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR SURGICAL COMPANY (Exact Name of Registra

STAAR Surgical Reports Record Second Quarter Net Sales of $81.1 Million Up 30% Y/Y ICL Units Up 42% Y/Y; Constant Currency Net Sales of $84.2 Million Announces Partnership with Joe Jonas to Raise EVO Global Awareness

Exhibit 99.1 STAAR Surgical Reports Record Second Quarter Net Sales of $81.1 Million Up 30% Y/Y ICL Units Up 42% Y/Y; Constant Currency Net Sales of $84.2 Million Announces Partnership with Joe Jonas to Raise EVO Global Awareness LAKE FOREST, CA, August 10, 2022 - STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery syst

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2022 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 15, 2022 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2022 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2022 or prospe

STAAR Surgical Investor Presentation NASDAQ: STAA | June 2022 Exhibit 99.1 All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2022 or prospects for achieving such plans, expectations for sales, revenue, margin, expe

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 7, 2022 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAAR Surgical Celebrates Two Million Lens Milestone for Implantable Collamer® Lens (ICL) Milestone Follows U.S. FDA Approval of EVO Visian® ICL in March EVO Offers Visual Freedom from Glasses and Contact Lenses

Exhibit 99.2 STAAR Surgical Celebrates Two Million Lens Milestone for Implantable Collamer? Lens (ICL) Milestone Follows U.S. FDA Approval of EVO Visian? ICL in March EVO Offers Visual Freedom from Glasses and Contact Lenses LAKE FOREST, CA, June 7, 2022 - STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for

MAY 04, 2022 / 8:30PM, STAA.OQ - Q1 2022 STAAR Surgical Co Earnings Call

Exhibit 99.1 MAY 04, 2022 / 8:30PM, STAA.OQ - Q1 2022 STAAR Surgical Co Earnings Call C O R P O R A T E P A R T I C I P A N T S Brian Moore STAAR Surgical Company - VP of Investor, Media Relations & Corporate Development Caren L. Mason STAAR Surgical Company - CEO, President & Director Patrick F. Williams STAAR Surgical Company - CFO C O N F E R E N C E C A L L P A R T I C I P A N T S Andrew Frede

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2022 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAAR Surgical Reports Record First Quarter Net Sales of $63.2 Million Up 25% Y/Y EVO Visian® ICL Lenses Received FDA Approval and First Lenses Implanted

Exhibit 99.1 STAAR Surgical Reports Record First Quarter Net Sales of $63.2 Million Up 25% Y/Y EVO Visian® ICL Lenses Received FDA Approval and First Lenses Implanted LAKE FOREST, CA, May 4, 2022 - STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the first qua

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: April 1, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR SURGICAL COMPANY (Exact Name of Registr

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2022 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEF 14A 1 staa-def14a20220616.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A 1 staa-defa14a20220616.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

PRE 14A 1 staa-pre14a20220616.htm PRE 14A SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Defini

STAAR Surgical Announces First Implants of EVO Visian ICL in the U.S. Announces Program of Meetings and Presentations at Upcoming ASCRS Annual Meeting

Exhibit 99.1 STAAR Surgical Announces First Implants of EVO Visian ICL in the U.S. Announces Program of Meetings and Presentations at Upcoming ASCRS Annual Meeting LAKE FOREST, CA, April 6, 2022 - STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced the first implants of the EVO Visia

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 6, 2022 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAAR Surgical Announces U.S. FDA Approval of EVO Visian® Implantable Collamer® Lenses EVO Lenses Provide Visual Freedom from Contact Lenses and Glasses Over One Million EVO Lenses Have Already Been Implanted Worldwide Information for Patients and Do

Exhibit 99.1 STAAR Surgical Announces U.S. FDA Approval of EVO Visian? Implantable Collamer? Lenses EVO Lenses Provide Visual Freedom from Contact Lenses and Glasses Over One Million EVO Lenses Have Already Been Implanted Worldwide Information for Patients and Doctor Finder at DiscoverEVO.com EVO Visian ICL, Envision A Life Without Hesitation. EVO Visian ICL Information and Animated Procedure. LAK

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 28, 2022 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2022 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

EDITED TRANSCRIPT

Exhibit 99.1 EDITED TRANSCRIPT STAA.OQ - Q4 2021 STAAR Surgical Co Earnings Call EVENT DATE/TIME: FEBRUARY 23, 2022 / 9:30PM GMT REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us ?2022 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without the prior writtenconsent of Refinitiv. 'Refinitiv' and the Ref

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-11634 STAAR SURGICAL C

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2022 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAAR Surgical Reports Fourth Quarter and Full Year 2021 Results

EX-99.1 2 staa-ex9916.htm EX-99.1 Exhibit 99.1 STAAR Surgical Reports Fourth Quarter and Full Year 2021 Results LAKE FOREST, CA, February 23, 2022 - STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the fourth quarter and fiscal year ended December 31, 2021. Fo

List of Subsidiaries.*

Exhibit 21.1 Subsidiaries of STAAR Surgical Company Name of Subsidiary Other Names Under Which it Does Business State or Other Jurisdiction of Incorporation STAAR Surgical UK LTD None United Kingdom STAAR Surgical AG None Switzerland STAAR Japan Inc. STAAR Japan Godo Kaisha Japan STAAR Surgical PTE. LTD None Singapore STAAR Optical Equipment Technology (Shanghai) Co., LTD None China STAAR Surgical

STAA / STAAR Surgical Company / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: STAAR Surgical Co. Title of Class of Securities: Common Stock CUSIP Number: 852312305 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ 

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 1, 2022 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAAR Surgical Investor Presentation NASDAQ: STAA | February 2022

STAAR Surgical Investor Presentation NASDAQ: STAA | February 2022 All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2022 or prospects for achieving such plans, expectations for sales, revenue, margin, expenses or e

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2022 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAAR Surgical Announces Preliminary Fourth Quarter and Full Year 2021 Results Achieves 40% Growth Y/Y with Full Year 2021 Net Sales of Approximately $230 Million Fourth Quarter Net Sales Approximately $59 Million

Exhibit 99.1 STAAR Surgical Announces Preliminary Fourth Quarter and Full Year 2021 Results Achieves 40% Growth Y/Y with Full Year 2021 Net Sales of Approximately $230 Million Fourth Quarter Net Sales Approximately $59 Million LAKE FOREST, CA, January 10, 2022- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems

NOVEMBER 03, 2021 / 8:30PM, STAA.OQ - Q3 2021 STAAR Surgical Co Earnings Call

Exhibit 99.1 Exhibit 99.1 NOVEMBER 03, 2021 / 8:30PM, STAA.OQ - Q3 2021 STAAR Surgical Co Earnings Call C O R P O R A T E P A R T I C I P A N T S Brian Moore STAAR Surgical Company - VP of Investor, Media Relations & Corporate Development Caren L. Mason STAAR Surgical Company - CEO, President & Director Patrick F. Williams STAAR Surgical Company - CFO C O N F E R E N C E C A L L P A R T I C I P A

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2021 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: October 1, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR SURGICAL COMPANY (Exact Name of Regis

STAAR Surgical Reports Third Quarter Net Sales of $58.4 Million Up 24% Y/Y Third Quarter ICL Sales Up 31% Y/Y and Units Up 29% Y/Y Increases Full Year 2021 Net Sales Outlook to Range of $230 Million to $231 Million

Exhibit 99.1 STAAR Surgical Reports Third Quarter Net Sales of $58.4 Million Up 24% Y/Y Third Quarter ICL Sales Up 31% Y/Y and Units Up 29% Y/Y Increases Full Year 2021 Net Sales Outlook to Range of $230 Million to $231 Million LAKE FOREST, CA, November 3, 2021 - STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery syste

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2021 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAA / STAAR Surgical Company / BROADWOOD PARTNERS, L.P. Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 23, 2021 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAA / STAAR Surgical Company / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: STAAR Surgical Co. Title of Class of Securities: Common Stock CUSIP Number: 852312305 Date of Event Which Requires Filing of this Statement: August 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Ru

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2021 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Investment Opportunity The Future of Refractive Surgery is Lens-Based... The Time for STAAR is Now 3

EX-99.1 2 staa-ex9917.htm EX-99.1 STAAR Surgical Company Investor presentation August 2021 Exhibit 99.1 Forward Looking Statements All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2021 or prospects for achieving s

AUGUST 04, 2021 / 8:30PM, STAA.OQ - Q2 2021 STAAR Surgical Co Earnings Call

Exhibit 99.1 AUGUST 04, 2021 / 8:30PM, STAA.OQ - Q2 2021 STAAR Surgical Co Earnings Call C O R P O R A T E P A R T I C I P A N T S Brian Moore STAAR Surgical Company - VP of Investor, Media Relations & Corporate Development Caren L. Mason STAAR Surgical Company - CEO, President & Director Patrick F. Williams STAAR Surgical Company - CFO C O N F E R E N C E C A L L P A R T I C I P A N T S Andrew Fr

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2021 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2021 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAAR Surgical Reports Record Second Quarter Net Sales of $62.4 Million Up 77% Y/Y and Increases Outlook for 2021 Second Quarter ICL Sales Up 93% Y/Y and Units Up 79% Y/Y Increases Full Year 2021 Net Sales Outlook to Range of $227 Million to $230 Mil

Exhibit 99.1 STAAR Surgical Reports Record Second Quarter Net Sales of $62.4 Million Up 77% Y/Y and Increases Outlook for 2021 Second Quarter ICL Sales Up 93% Y/Y and Units Up 79% Y/Y Increases Full Year 2021 Net Sales Outlook to Range of $227 Million to $230 Million LAKE FOREST, CA, August 4, 2021 - STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantab

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: July 2, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR SURGICAL COMPANY (Exact Name of Registra

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 24, 2021 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAA / STAAR Surgical Company / BROADWOOD PARTNERS, L.P. Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 26, 2021 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Investment Opportunity The Future of Refractive Surgery is Lens-Based... The Time for STAAR is Now 3

STAAR Surgical Company Investor presentation May 2021 Exhibit 99.1 Forward Looking Statements All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2021 or prospects for achieving such plans, expectations for sales, re

STAAR Surgical Q1 2021 Earnings Call Transcript

Exhibit 99.1 STAAR Surgical Q1 2021 Earnings Call Transcript Date: May 5, 2021 CORPORATE PARTICIPANTS Caren Mason, President, Chief Executive Officer & Director, STAAR Surgical Patrick F. Williams, Chief Financial Officer, STAAR Surgical Brian Moore, Vice President-Investor, Media Relations and Corporate Development, STAAR Surgical OTHER PARTICIPANTS Anthony Petrone, Analyst, Jefferies LLC MANAGEM

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2021 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAAR Surgical Reports Record First Quarter 2021 Net Sales of $50.8 Million Up 44% Y/Y First Quarter ICL Sales Up 58% Y/Y and Units Up 54% Y/Y Announces Submission of Clinical Trial Data to U.S. FDA for EVO Family of Myopia Lenses Introduces Net Sale

Exhibit 99.1 STAAR Surgical Reports Record First Quarter 2021 Net Sales of $50.8 Million Up 44% Y/Y First Quarter ICL Sales Up 58% Y/Y and Units Up 54% Y/Y Announces Submission of Clinical Trial Data to U.S. FDA for EVO Family of Myopia Lenses Introduces Net Sales Outlook of Approximately $215 Million to $217 Million for Full Year 2021 LAKE FOREST, CA, May 5, 2021 - STAAR Surgical Company (NASDAQ:

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2021 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: April 2, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR SURGICAL COMPANY (Exact Name of Registr

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 26)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2021 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAAR Surgical Q4 2020 Earnings Call Transcript

EX-99.1 2 staa-ex9916.htm EX-99.1 Exhibit 99.1 STAAR Surgical Q4 2020 Earnings Call Transcript Date: February 24, 2021 CORPORATE PARTICIPANTS Caren Mason, President, Chief Executive Officer & Director, STAAR Surgical Patrick F. Williams, Chief Financial Officer, STAAR Surgical Brian Moore, Vice President-Investor, Media Relations and Corporate Development, STAAR Surgical OTHER PARTICIPANTS Chris C

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2021 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

List of Subsidiaries.*

Exhibit 21.1 Subsidiaries of STAAR Surgical Company Name of Subsidiary Other Names Under Which it Does Business State or Other Jurisdiction of Incorporation STAAR Surgical UK LTD None United Kingdom STAAR Surgical AG None Switzerland STAAR Japan Inc. STAAR Japan Godo Kaisha Japan STAAR Surgical PTE. LTD None Singapore STAAR Optical Equipment Technology (Shanghai) Co., LTD None China STAAR Surgical

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 1, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-11634 STAAR SURGICAL COM

STAAR Surgical Reports Fourth Quarter and Full Year 2020 Results

Exhibit 99.1 STAAR Surgical Reports Fourth Quarter and Full Year 2020 Results LAKE FOREST, CA, February 24, 2021 - STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the fourth quarter and fiscal year ended January 1, 2021. Fourth Quarter 2020 Overview • Net Sal

- S-3/A

As filed with the Securities and Exchange Commission on February 19, 2021 Registration No.

-

STAAR Surgical Company 25651 Atlantic Ocean Drive Lake Forest, CA 92630 February 18, 2021 Via EDGAR Division of Corporation Finance U.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: STAAR Surgical Co. Title of Class of Securities: Common Stock CUSIP Number: 852312305 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 25)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

Elizabeth Yeu, M.D. and K. Peony Yu, M.D. Appointed to STAAR Surgical Board of Directors

Exhibit 99.1 Elizabeth Yeu, M.D. and K. Peony Yu, M.D. Appointed to STAAR Surgical Board of Directors LAKE FOREST, CA, January 26, 2021 - STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced the appointments of Elizabeth Yeu, M.D., Partner, Virginia Eye Consultants, and K. Peony Yu, M

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 26, 2021 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 ATTENTION: Transmit for filing 3 copies of this form concurrently with either placing an order with a broker to execute sale or executing a sale directly with a market maker. OMB APPROVAL OMB Number: Expires: Estimated average

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 11, 2021 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAAR Surgical Announces Preliminary Fourth Quarter and Full Year 2020 Results Net Sales Approximately $46 Million in Fourth Quarter and $163 Million for Full Year

EX-99 2 staa-ex996.htm EX-99 Exhibit 99.1 STAAR Surgical Announces Preliminary Fourth Quarter and Full Year 2020 Results Net Sales Approximately $46 Million in Fourth Quarter and $163 Million for Full Year LAKE FOREST, CA, January 10, 2021- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today p

STAAR Surgical Q3 2020 Earnings Call Transcript

Exhibit 99.1 STAAR Surgical Q3 2020 Earnings Call Transcript Date: November 4, 2020 CORPORATE PARTICIPANTS Caren Mason, President, Chief Executive Officer & Director, STAAR Surgical Patrick F. Williams, Chief Financial Officer, STAAR Surgical Brian Moore, Vice President-Investor, Media Relations and Corporate Development, STAAR Surgical OTHER PARTICIPANTS Anthony Petrone, Analyst, Jefferies LLC Ch

Regulation FD Disclosure, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 4, 2020 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAAR Surgical Reports Third Quarter 2020 Results

Exhibit 99.1 STAAR Surgical Reports Third Quarter 2020 Results LAKE FOREST, CA, November 4, 2020 - STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the third quarter ended October 2, 2020. Third Quarter 2020 Overview • Record Quarterly Net Sales of $47.1 Milli

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: October 2, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR SURGICAL COMPANY (Exact Name of Regis

Regulation FD Disclosure, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 4, 2020 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

First Amendment to Lease Agreement dated October 30, 2020 between STAAR Surgical Company and 2000 Gold L.P.*

Exhibit 10.41 2000 Gold Limited Partnership 2530 Corporate Pl Suite A210 Monterey Park, CA 97145 Telephone: 323 406 2388 Fax: 323 406 2391 AMENDMENT NO. 1 TO LEASE THIS AMENDMENT No. 1 TO LEASE (“Amendment”) is entered into as of October 30, 2020 by and between 2000 Gold L.P., a California Limited Partnership (“Lessor”) and STAAR SURGICAL COMPANY, a Delaware Corporation (“Lessee”), with reference

First Amendment by and between the Company and Pacific Equity Partners, LLC.

Exhibit 10.40 FIRST AMENDMENT DATED SEPTEMBER 11, 2020 ("FIRST AMENDMENT") TO STANDARD INDUSTRIAL/COMMERCIAL SINGLE-TENANT LEASE – NET DATED AUGUST 8, 2012 ("LEASE") BETWEEN PACIFIC EQUITY PARTNERS, LLC, A CALIFORNIA LIMITED LIABILITY COMPANY ("LESSOR"), AND STAAR SURGICAL COMPANY, A DELAWARE CORPORATION ("LESSEE") This First Amendment modifies and amends the Lease as follows: 1. Expiration Date T

Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 1, 2020 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAAR Surgical Announces Completion of Patient Enrollment in EVO Implantable Lens US Clinical Trial Pivotal Study Successfully Enrolls 300 Subjects Across 14 U.S. Sites

Exhibit 99.1 STAAR Surgical Announces Completion of Patient Enrollment in EVO Implantable Lens US Clinical Trial Pivotal Study Successfully Enrolls 300 Subjects Across 14 U.S. Sites LAKE FOREST, CA, September 14, 2020- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, is today announcing that pati

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 14, 2020 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Lease Agreement entered into on September 14, 2020 between Calderari & Schwab and STAAR Surgical AG

1 Exhibit 10.39 6g.b .REALESTATE & MANAGEMENT Lease Agreement between Calderari & Schwab, Schlossstrasse 8a, 2560 Nidau Enzo Calderari, Neuenburgstrasse 36, 2505 Biel Walter Schwab, Kirschbaumweg 8, 2572 Mortars and Staar Surgical AG, Hauptstrasse 104, 2560 Nidau 1. Rental Property In the building at Hauptstrasse 104 in 2560 Nidau, the tenant takes over the following premises for rent over a total

Forward Looking Statements All statements in this presentation that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections, plans, strategies, and objectives of

STAAR Surgical Company Investor presentation September 2020 Exhibit 99.1 Forward Looking Statements All statements in this presentation that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections, plans, strategies, and objectives of management for 2020 or prospects for achieving such plans, expectations for

Regulation FD Disclosure, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 2, 2020 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

STAA / Staar Surgical Co. / BROADWOOD PARTNERS, L.P. Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2020 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 0-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Forward Looking Statements All statements in this presentation that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections, plans, strategies, and objectives of

STAAR Surgical Company Investor presentation August 11-12, 2020 Exhibit 99.1 Forward Looking Statements All statements in this presentation that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections, plans, strategies, and objectives of management for 2020 or prospects for achieving such plans, expectations